To examine the effect of the Smad3 signaling pathway on EGFR expression in breast cancer cells, the cells were pretreated with the TGF‐β receptor inhibitor SB431542 and then stimulated with TGF‐β. This evidence concerns the gene TGFB1 and breast cancer.